|
Year
|
Title
|
Authors
|
Publication
|
|
2020
|
Prognostic Impact of Serum CXC Chemokine Ligands 4 and 7 on Myelodysplastic Syndromes Post Allogeneic Hematopoietic Cell Transplant
|
Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon Y-T, Carlson K-S, Nazha A, Saber W
|
Leuk Lymphoma
|
|
2020
|
The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization.
|
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Hashmi S, Parsons S, Wood WA, Steinberg A, Freytes CO, Dandoy CE, Marks DI, Lazarus HM, Abdel-Azim H, Bitan M, Diaz MA, Olsson RF, Gergis U, Seber A, Wirk B, LeMaistre CF, Ustun C, Duncan C, Rizzieri D, Szwajcer D, Fagioli F, Frangoul H, Knight JM, Kamble RT, Mehta PA, Schears R, Satwani P, Pulsipher MA, Aplenc R, Saber W
|
Biol Blood Marrow Transplant 26(9):1747-1756
|
|
2020
|
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
|
Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer E, Rosinol L, Krishnan AY, Gahrton G, Bruno B
|
Bone Marrow Transplant 55(9):1810-1816
|
|
2020
|
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
|
Herr MM, Curtis RE, Tucker MA, Tecca HR, Engels EA, Cahoon EK, Battiwalla M, Buchbinder D, Flowers ME, Brazauskas R, Shaw BE, Morton LM
|
J Am Acad Dermatol 83(3):762-772
|
|
2020
|
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: Long term follow up of a novel high dose regimen.
|
Hagen P, D'Souza A, Hari P, Davila O, Zhang M-J, Vesole D, Smith SE, Rodriguez TE, Stiff PJ
|
Leuk Lymphoma
|
|
2020
|
Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101)
|
Fuchs E, O'Donnell P, Eapen M, Logan BR, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau J, McGuirk J, Morris L, Rezvani A, Jones RJ, Brunstein C
|
Blood
|
|
2020
|
The global state of hematopoietic cell transplantation for multiple myeloma: An analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study.
|
Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, Greinix H, Koh M, Worel N, Libby EN, Pasquini M, Galeano S, Saber W, Iida M, Jaimovich G, Rolon JM, Kodera Y, Benakli M, Nosa BG, Elhaddad A, Szer J, Passweg J, Kroeger N, Weisdorf D, Niederwieser D
|
Biol Blood Marrow Transplant
|
|
2020
|
Health-related quality-of-life comparison of adult related and unrelated HSC donors: An RDSafe study.
|
Switzer GE, Bruce JG, Kiefer D, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA
|
Biol Blood Marrow Transplant
|
|
2020
|
Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation.
|
Petersdorf EW, Bengtsson M, De Santis D, Dubois V, Fleischhauer K, Gooley T, Horowitz M, Madrigal JA, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P, Carrington M
|
J Clin Oncol 38(24):2712-2718
|
|
2020
|
The effect of G-CSF use on hospital length of stay after an allogeneic hematopoietic cell transplantation: A retrospective multicenter cohort study.
|
George G, Martin AS, Chhabra S, Eapen M
|
Biol Blood Marrow Transplant
|
|
2020
|
Short telomere length predicts non-relapse mortality after stem cell transplantation for myelodysplastic syndrome.
|
Myllymäki M, Redd R, Reilly CR, Saber W, Spellman S, Gibson CJ, Hu Z-H, Wang T, Orr EH, Grenier JG, Chen MM, Steensma DP, Cutler C, De Vivo I, Antin JH, Neuberg D, Agarwal S, Lindsley RC
|
Blood
|
|
2020
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
|
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Paquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, San Miguel J, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B
|
Leukemia
|
|
2020
|
A personalized prediction model for outcomes after allogeneic hematopoietic cell transplant in myelodysplastic syndromes patients.
|
Nazha A, Hu Z-H, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Saber W
|
Biol Blood Marrow Transplant
|
|
2020
|
Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide.
|
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn J-Y, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales M-A, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK
|
Biol Blood Marrow Transplant 26(8):1459-1468
|
|
2020
|
Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome.
|
Myers K, Hebert K, Antin J, Boulad F, Burroughs L, Hofmann I, Kamble R, MacMillan ML, Eapen M
|
Biol Blood Marrow Transplant 26(8):1446-1451
|
|
2020
|
Return-to-work guidelines and programs for post-hematopoietic cell transplantation survivors: An initial survey.
|
Salit RB, Lee SJ, Burns LJ, Shaw BE, Majhail N, Bhatt N, Wood WA, Syrjala KL
|
Biol Blood Marrow Transplant 26(8):1520-1526
|
|
2020
|
Current use of and trends in hematopoietic cell transplantation in the United States.
|
D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM
|
Biol Blood Marrow Transplant 26(8):e177-182
|
|
2020
|
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.
|
Brazauskas R, Scigliuolo GM, Wang HL, Cappelli B, Ruggeri A, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Panepinto JA, Rondelli D, Shenoy S, Walters MC, Wagner JE, Tisdale JF, Gluckman E, Eapen M
|
Blood 136(5):623-626
|
|
2020
|
Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee.
|
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales M-A, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK
|
Biol Blood Marrow Transplant
|
|
2020
|
HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation.
|
Petersdorf EW, Stevenson P, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Carrington M
|
Blood 136(3):362-369
|
|
2020
|
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: A CIBMTR report.
|
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn J-Y, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales M-A, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W
|
Blood Adv 4(13):3180-3190
|
|
2020
|
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
|
Hu B, Lin X, Lee HC, Huang X, Slack Tidwell RS, Ahn KW, Hu Z-H, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Sohl M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, De Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W
|
Leuk Lymphoma
|
|
2020
|
Ixazomib for chronic graft-versus-host disease prophylaxis following allogeneic hematopoietic cell transplantation.
|
Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang M-J, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M
|
Biol Blood Marrow Transplant
|
|
2020
|
Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.
|
Solomon SR, Martin AS, Zhang MJ, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LA, Brunstein C, Chhabra S, Perez MAD, Fuchs EJ, Ganguly S, Hardy N, Hematti P, McGuirk J, Peres E, Ringden O, Rizzieri D, Romee R, Solh M, Szwajcer D, van der Poel M, Waller EK, William BM, Eapen M
|
Biol Blood Marrow Transplant
|
|
2020
|
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
|
Nikiforow S, Mansour M, Hu Z-H, Horowitz MM, Riches M, Hematti P, Turtle CJ, Zhang M-J, Perales M-A, Pasquini MC, Frigault MJ
|
Blood 136(1):137-139
|
|
2020
|
Curability and transferability of atopy with allogeneic hematopoietic cell transplantation.
|
Whiteside S, Chin A, Tripathi G, Dharmani-Khan P, Markova M, Keslova P, Sedlacek P, Geddes MN, Lewis V, Modi M, Kalra A, Dabas R, Akhter A, Larratt L, van Slyke T, Brandwein J, Spellman SR, Leigh R, Daly A, Khan FM, Storek J
|
Bone Marrow Transplant 55(7):1282-1289
|
|
2020
|
Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant.
|
Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M
|
JAMA Oncol 6(7):1011-1018
|
|
2020
|
Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.
|
Martens MJ, Logan BR
|
Lifetime Data Anal 26(3):603-623
|
|
2020
|
Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis.
|
Hamadani M, Zhang M-J, Tang X-Y, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM
|
Biol Blood Marrow Transplant 26(7):1312-1317
|
|
2020
|
Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia.
|
Eapen M, Zhang M-J, Tang X-Y, Lee SJ, Fei M-W, Wang H-L, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM
|
Biol Blood Marrow Transplant 26(7):e161-e166
|
|
2020
|
Geriatric assessment in older alloHCT recipients: Association of functional and cognitive impairment with outcomes.
|
Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang L-W, Koll T, Lee SM, Lin RJ, Pang L, Popat UR, Weisdorf DJ, Artz A
|
Blood Adv 4(12):2810-2820
|
|
2020
|
Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
|
Holstein S, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL
|
Biol Blood Marrow Transplant
|
|
2020
|
Composite GRFS and CRFS outcomes after adult alternative donor HCT.
|
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn J-Y, Weisdorf DJ
|
J Clin Oncol 38(18):2062-2076
|
|
2020
|
Comparison of Total body irradiation versus non- Total body irradiation containing regimens for de novo acute myeloid leukemia in children.
|
Dandoy CE, Davies SM, Ahn KW, He Y, Kolb AE, Bo-Subait S, Abdel-Azim H, Bhatt N, Chewing J, Gadalla S, Gloude N, Hayashi R, Lalefar NR, Law J, MacMillan M, O'Brien T, Prestidge T, Sharma A, Shaw P, Eapen M, Levine J
|
Haematologica
|
|
2020
|
Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: A CIBMTR analysis.
|
Farhadfar N, Murthy HS, Logan BR, Sees JA, Mouhab A, Battiwalla M, Beitinjaneh A, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O'Donnell PV, Olsson RF, Rossmann SN, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR
|
Bone Marrow Transplant
|
|
2020
|
Analysis of the whole CDR3 T cell receptor repertoire after hematopoietic stem cell transplantation in 2 clinical cohorts.
|
Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, Rangarajan K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH
|
Biol Blood Marrow Transplant 26(6):1050-1070
|
|
2020
|
Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes.
|
Cusatis RN, Tecca HR, D'Souza A, Shaw BE, Flynn KE
|
Cancer 126(11):2679-2686
|
|
2020
|
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): Accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
|
Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Odunsi A
|
J Immunol 8(1):e000796
|
|
2020
|
Rapid donor identification improves survival in high-risk first-remission patients with acute myeloid leukemia.
|
Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer R-L, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR
|
JCO Oncol Pract 16(6):e464-e475
|
|
2020
|
Higher total body irradiation dose intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation.
|
Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT
|
Biol Blood Marrow Transplant 26(6):1099-1105
|
|
2020
|
The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era.
|
Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W
|
Biol Blood Marrow Transplant 26(6):1137-1143
|
|
2020
|
Collection of peripheral blood progenitor cells in 1 day is associated with decreased donor toxicity compared to 2 days in unrelated donors.
|
Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredeson C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugrue M, Warkentin P, Wingard JR
|
Biol Blood Marrow Transplant 26(6):1210-1217
|
|
2020
|
Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy.
|
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M
|
Br J Haematol 189(6):1171-1181
|
|
2020
|
Clonal hematopoiesis in related allogeneic transplant donors: implications for screening and management.
|
Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, Shaw BE
|
Biol Blood Marrow Transplant 26(6):e142-e144
|
|
2020
|
Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
|
Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M
|
Cancer 126(10):2279-2287
|
|
2020
|
Survival following allogeneic transplant in patients with myelofibrosis.
|
Gowin K, Ballen K, Ahn KW, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W
|
Blood Adv 4(9):1965-1973
|
|
2020
|
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
|
Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P
|
Blood Adv 4(9):2084-2094
|
|
2020
|
Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
|
Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales M-A, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang M-J, Gluckman E, Montoto S, Eapen M
|
J Clin Oncol 38(14):1518-1526
|
|
2020
|
Prior gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research analysis.
|
Ho VT, Martin AS, Pérez WS, Steinert P, Zhang M-J, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W
|
Biol Blood Marrow Transplant 26(5):884-892
|
|
2020
|
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: A study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
|
Lazaryan A, Dolan M, Zhang M-J, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Maijhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Malki MA, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D
|
Haematologica 105(5):1329-1338
|
|
2020
|
Healthcare costs of treating privately insured patients with acute myeloid leukemia in the United States from 2004 to 2014: A generalized additive modeling approach.
|
Mau L-W, Preussler JM, Burns LJ, Leppke S, Majhail NS, Meyer CL, Mupfudze T, Saber W, Steinert P, Vanness DJ
|
PharmacoEconomics 38(5):515-526
|
|
2020
|
Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults.
|
Majhail NS, Mau L-W, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, LeMaistre CF, Loberiza F, Parsons SK, Repaczki-Jones R, Robinett P, Douglas Rizzo J, Murphy E, Logan B, Le-Rademacher J
|
Bone Marrow Transplant 55(5):906-917
|
|
2020
|
Population frequency of Fanconi pathway gene variants and their association with survival after hematopoietic cell transplantation for severe aplastic anemia.
|
McReynolds LJ, Wang Y, Thompson AS, Ballew BJ, Kim J, Alter BP, Hicks B, Zhu B, Jones K, Spellman SR, Wang T, Lee SJ, Savage SA, Gadalla SM
|
Biol Blood Marrow Transplant 26(5):817-822
|
|
2020
|
Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: A CIBMTR analysis.
|
Farhadfar N, Murthy HS, Logan BR, Sees JA, Mouhab A, Battiwalla M, Beitinjaneh A, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Geris U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O'Donnell PV, Olsson RF, Rossman SN, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR
|
Bone Marrow Transplant
|
|
2020
|
Engaging hematopoietic cell transplantation patients and caregivers in the design of print and mobile individualized survivorship care plan tools.
|
Preussler JM, Denzen EM, Majhail NS, Baker KS, McCann M, Burns LJ, Yi J, Syrjala KL
|
Support Care Cancer 28(6):2805-2816
|
|
2020
|
Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
|
Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M
|
Br J Haematol
|
|
2020
|
Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease.
|
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME
|
J Clin Oncol 38(12):1273-1283
|
|
2020
|
Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia.
|
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ
|
Blood Adv 4(7):1350-1356
|
|
2020
|
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
|
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer R-L, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A
|
Leukemia
|
|
2020
|
The changing landscape of treatment in acute
myeloid leukemia.
|
Koenig K, Mims A, Levis MJ, Horowitz MM
|
Am Soc Clin Oncol Educ Book 40:1-12
|
|
2020
|
Comparison of patient age groups in transplantation for myelodysplastic syndrome: The Medicare coverage with evidence development study.
|
Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD
|
JAMA Oncol 6(4):486-493
|
|
2020
|
Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: Long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
|
Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E
|
Biol Blood Marrow Transplant 26(4):798-804
|
|
2020
|
Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: Still a role for allogeneic transplantation?
|
Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M
|
Biol Blood Marrow Transplant 26(4):e77-e85
|
|
2020
|
Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: A study of 2456 umbilical cord blood recipients.
|
Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, Drexler RJ, Duffy M, Kemp A, King R, Babic A, Delaney C, Karanes C, Kurtzberg J, Petz L, Scaradavou A, Shpall EJ, Smith C, Confer DL, Miller JP
|
Biol Blood Marrow Transplant 26(4):745-757
|
|
2020
|
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
|
Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS
|
Blood Adv 4(6):983-992
|
|
2020
|
Predictors of loss to follow-up among pediatric and adult hematopoietic cell transplantation survivors: A report from the Center for International Blood and Marrow Transplant Research.
|
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar AJ, Yoshimi A, Wirk B, Shaw B, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy S, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W
|
Biol Blood Marrow Transplant 26(3):553-561
|
|
2020
|
Follistatin and soluble endoglin predict 1-year nonrelapse mortality after allogeneic hematopoietic cell transplantation.
|
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG
|
Biol Blood Marrow Transplant 26(3):606-611
|
|
2020
|
Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: A Center for International Blood and Marrow Transplant Research Study.
|
DeFilipp Z, Ancheta R, Liu Y, Hu Z-H, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn J-Y, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W
|
Biol Blood Marrow Transplant 26(3):472-479
|
|
2020
|
Direct adjusted survival and cumulative incidence curves for observational studies.
|
Hu Z-H, Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(3):538-543
|
|
2020
|
Weighty choices: Selecting optimal G-CSF doses for stem cell mobilization to optimize yield.
|
Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR
|
Blood Adv 4(4):706-716
|
|
2020
|
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
|
Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS
|
Blood Adv 4(4):750-754
|
|
2020
|
Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia.
|
Savage SA, Viard M, O'hUigin C, Zhou W, Yeager M, Li SA, Wang T, Ramsuran V, Vince N, Vogt A, Hicks B, Burdett L, Chung C, Dean M, de Andrade KC, Freedman ND, Berndt SI, Rothman N, Lan Q, Cerhan JR, Slager SL, Zhang Y, Teras LR, Haagenson M, Chanock SJ, Spellman SR, Wang Y, Willis A, Askar M, Lee SJ, Carrington M, Gadalla SM
|
Am J Hum Genet 106(2):264-271
|
|
2020
|
Comprehensive prognostication in critically ill pediatric hematopoietic cell transplant patients: Results from merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.
|
Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC
|
Biol Blood Marrow Transplant 26(2):333-342
|
|
2020
|
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: Young HLA-matched unrelated or haploidentical donor?
|
Perales M-A, Tomlinson B, Zhang M-J, St. Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M
|
Haematologica 105(2):407-413
|
|
2020
|
Priorities for improving outcomes for non-malignant blood diseases: A report from the Blood and Marrow Transplant Clinical Trials Network.
|
Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N
|
Biol Blood Marrow Transplant
|
|
2020
|
Pre‐transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia.
|
Wang Y, McReynolds LJ, Dagnall C, Katki HA, Spellman SR, Wang T, Hicks B, Freedman ND, Jones K, Lee SJ, Savage SA, Gadalla SM
|
Br J Haematol 188(2):309-316
|
|
2020
|
Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation.
|
Wong WH, Bhatt S, Trinkaus K, Pusic I, Elliott K, Mahajan N, Wan F, Switzer GE, Confer DL, DiPersio J, Pulsipher MA, Shah NN, Sees J, Bystry A, Blundell JR, Shaw BE, Druley TE
|
Sci Transl Med 12(526):1-9
|
|
2020
|
Health care reimbursement, service utilization, and financial responsibility among Medicare beneficiaries with multiple myeloma receiving autologous hematopoietic cell transplantation in inpatient and outpatient settings.
|
Dunavin N, Mau L-W, Meyer CL, Divine C, Leppke S, D'Souza A, Denzen E, Saber W, Burns LJ, Ganguly S
|
Biol Blood Marrow Transplant
|
|
2020
|
Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant.
|
Dandoy CE, Kim S, Chen M, Ahn K-W, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales M-A, Lindemans CA, Komanduri KV, Riches ML
|
JAMA Netw Open 3(1):e1918668
|
|
2020
|
Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: A retrospective cohort study.
|
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P
|
Lancet Haematol 7(1):e50-e60
|
|
2020
|
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
|
Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL
|
Biol Blood Marrow Transplant 26(1):e7-e15
|
|
2020
|
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: The BMT CTN 1501 trial.
|
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML
|
Blood 135(2):97-107
|
|
2020
|
Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky.
|
Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):1-3
|
|
2020
|
Causal inference in randomized clinical trials.
|
Zheng C, Dai R, Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):4-8
|
